News
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022
EQS-News: Evotec completes acquisition of Central Glass Germany
EQS-News: Evotec completes acquisition of Central Glass Germany
EQS-News: STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022
EQS-News: STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day
Dexcom Partners With Warriors and Nonprofits to Artfully Advocate for Access to Diabetes Care
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes will come together with members of the diabetes community during National Diabetes
Dexcom Partners With Warriors and Nonprofits to Artfully Advocate for Access to Diabetes Care
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes will come together with members of the diabetes community during National Diabetes
CORRECTING and REPLACING Acadia Healthcare Reports Third Quarter 2022 Results
There was an inadvertent error on the supplementary table titled “Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted Income Attributable to Acadia Healthcare
EQS-Adhoc: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
EQS-Adhoc: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
EQS-News: Fresenius Medical Care AG & Co. KGaA revises financial outlook for full year 2022
EQS-News: Fresenius Medical Care AG & Co. KGaA revises financial outlook for full year 2022
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA extends net income target range for financial year 2022
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA extends net income target range for financial year 2022
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases
EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases
Dexcom, Adam Schefter Announce Dexcom U, the First NIL Program for College Athletes With Diabetes
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of Dexcom U, the first-ever NIL (name, image
Dexcom, Adam Schefter Announce Dexcom U, the First NIL Program for College Athletes With Diabetes
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of Dexcom U, the first-ever NIL (name, image
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST NINE MONTHS OF 2022 AND ADJUSTS SALES GUIDANCE
EQS-Adhoc: STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST NINE MONTHS OF 2022 AND ADJUSTS SALES GUIDANCE
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
CORRECTING and REPLACING Humana Announces Major Expansion of Florida Dental Network, Benefits
First bullet point under More Help for Floridians Eligible for Both Medicare and Medicaid section of release dated October 17, 2022, should read: Healthy Options Allowance provides eligible members